NCT06300424View on ClinicalTrials.gov

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2027

Conditions
Non Small Cell Lung CancerEGFR Gene Mutation
Interventions
DRUG

almonertinib

110mg qd

DRUG

Carboplatin

AUC 5, d1 every 3 weeks

DRUG

Nab paclitaxel

135 mg/m2, d1,d8 every 3 weeks

Trial Locations (1)

510080

RECRUITING

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER